BioSpace News Archive

Pleural Dynamics, a medical device company that is building solutions for chronic, recurrent fluid collections in the body, today announced that the Company has initiated “The ACES Study for Aseptic Pleural Effusions,” a post-market clinical study for the ACES™ Automatic Continuous Effusion Shunt System with the first device implantation performed at the University of North Carolina.

Medasense, a global leader in pain monitoring solutions, is proud to announce a strategic partnership with Nihon Kohden for the exclusive distribution of its revolutionary pain monitoring device in Japan.

Rivus Pharmaceuticals today announced publication of the rationale and design of the company’s Phase 2a HuMAIN trial in the European Journal of Heart Failure.

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Sona’s Chief Medical Officer and the Study’s principal investigator, Dr. Carman Giacomantonio, commented, “With two separate murine cancer models completed, we now believe it is clear that Sona’s THT therapy causes cancer specific proteins (cancer antigens) to become visible to the immune system.

Quest Diagnostics and Allina Health announced a definitive agreement for Quest to acquire select laboratory assets from Allina Health, with the goal to improve access to and the affordability of innovative laboratory services across Minnesota and western Wisconsin.

Tonix Pharmaceuticals Holding Corp. today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

MiMedx Group, Inc. announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company’s Senior Vice President, Sales since August 2020.

On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.